HeartFlow, Inc. (HTFL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High
The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.
HeartFlow: An Impressive MedTech Growth Play
HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
Heartflow Q2 Earnings Call Highlights
Heartflow NASDAQ: HTFL reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results.
HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates
HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago.
HeartFlow: A Premium AI Diagnostics Story
I recommend a buy rating for HeartFlow, Inc. due to its strong clinical workflow integration and expanding product suite. HTFL's AI-enabled platform, anchored by FFRCT and Plaque Analysis, drives adoption, monetization, and workflow efficiency in coronary artery disease diagnosis. Plaque Analysis, validated and soon to have its own billing code, broadens HTFL's addressable market and supports incremental revenue growth from existing CCTA scans.
Heartflow Q1 Earnings Call Highlights
Heartflow NASDAQ: HTFL reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market.
HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript
HeartFlow: Getting Into The Flow
HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. 2026 guidance targets 25% revenue growth to $218–222 million, with gross margins rising to 80–81% and further mid-term upside to 85%. HearthFlow's AI-driven CAD diagnostic platform is gaining adoption, supported by FDA-cleared next-generation algorithms and a proprietary CT image database.
HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript
Bamco Inc. NY Takes $41.65 Million Position in Heartflow, Inc. $HTFL
Bamco Inc. NY purchased a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,506 shares of the company's stock, valued at approximately $41,654,000. Bamco Inc. NY owned about 1.45% of Heartflow at the end of the
Capital International Investors Invests $43.67 Million in Heartflow, Inc. $HTFL
Capital International Investors purchased a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,297,423 shares of the company's stock, valued at approximately $43,671,000. Capital International Investors owned 1.56% of Heartflow
